Biotech
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
This browser does not support voice playback. Try Chrome, Edge or Safari.